Effect of Lactobacillus gasseri SBT2055 in fermented milk on abdominal adiposity in adults in a randomised controlled trial - PubMed (original) (raw)
Randomized Controlled Trial
. 2013 Nov 14;110(9):1696-703.
doi: 10.1017/S0007114513001037. Epub 2013 Apr 25.
Affiliations
- PMID: 23614897
- DOI: 10.1017/S0007114513001037
Randomized Controlled Trial
Effect of Lactobacillus gasseri SBT2055 in fermented milk on abdominal adiposity in adults in a randomised controlled trial
Yukio Kadooka et al. Br J Nutr. 2013.
Abstract
Consumption of fermented milk (FM) containing a probiotic, Lactobacillus gasseri SBT2055 (LG2055), previously showed a reduction in abdominal adiposity in a randomised controlled trial (RCT) using FM with 10(8) colony-forming units (cfu) of LG2055/g. However, whether the effectiveness is observed at lower concentrations, the recommended minimum or intermediate levels of probiotics (10(6) or 10(7) cfu/g, respectively), remains to be examined. A multi-centre, double-blind, parallel-group RCT was conducted using 210 healthy Japanese adults with large visceral fat areas (80·2 - 187·8 cm(2)). They were balanced for their baseline characteristics and randomly assigned to three groups receiving FM containing 10(7), 10(6) or 0 (control) cfu LG2055/g of FM, and were asked to consume 200 g FM/d for 12 weeks. Abdominal visceral fat areas, which were determined by computed tomography, at week 12, changed from baseline by an average of -8·5 % (95 % CI -11·9, -5·1; P< 0·01) in the 10(7) dose group, and by -8·2 % (95 % CI -10·8, -5·7; P< 0·01) in the 10(6) dose group. Other measures including BMI, waist and hip circumferences, and body fat mass were also significantly decreased from baseline at week 12 in both groups; interestingly, the cessation of taking FM for 4 weeks attenuated these effects. In the control group, none of these parameters significantly decreased from baseline. These findings demonstrate that consumption of LG2055 at doses as low as the order of 10(8) cfu/d exhibited a significant lowering effect on abdominal adiposity, and suggest that constant consumption might be needed to maintain the effect.
Similar articles
- Regulation of abdominal adiposity by probiotics (Lactobacillus gasseri SBT2055) in adults with obese tendencies in a randomized controlled trial.
Kadooka Y, Sato M, Imaizumi K, Ogawa A, Ikuyama K, Akai Y, Okano M, Kagoshima M, Tsuchida T. Kadooka Y, et al. Eur J Clin Nutr. 2010 Jun;64(6):636-43. doi: 10.1038/ejcn.2010.19. Epub 2010 Mar 10. Eur J Clin Nutr. 2010. PMID: 20216555 Clinical Trial. - Lactobacillus gasseri SBT2055 reduces postprandial and fasting serum non-esterified fatty acid levels in Japanese hypertriacylglycerolemic subjects.
Ogawa A, Kadooka Y, Kato K, Shirouchi B, Sato M. Ogawa A, et al. Lipids Health Dis. 2014 Feb 19;13:36. doi: 10.1186/1476-511X-13-36. Lipids Health Dis. 2014. PMID: 24548293 Free PMC article. Clinical Trial. - Lactobacillus gasseri SBT2055 suppresses fatty acid release through enlargement of fat emulsion size in vitro and promotes fecal fat excretion in healthy Japanese subjects.
Ogawa A, Kobayashi T, Sakai F, Kadooka Y, Kawasaki Y. Ogawa A, et al. Lipids Health Dis. 2015 Mar 20;14:20. doi: 10.1186/s12944-015-0019-0. Lipids Health Dis. 2015. PMID: 25884980 Free PMC article. Clinical Trial. - Visceral adiposity and inflammatory bowel disease.
Rowan CR, McManus J, Boland K, O'Toole A. Rowan CR, et al. Int J Colorectal Dis. 2021 Nov;36(11):2305-2319. doi: 10.1007/s00384-021-03968-w. Epub 2021 Jun 9. Int J Colorectal Dis. 2021. PMID: 34104989 Review. - Beverage Consumption and Growth, Size, Body Composition, and Risk of Overweight and Obesity: A Systematic Review [Internet].
Mayer-Davis E, Leidy H, Mattes R, Naimi T, Novotny R, Schneeman B, Kingshipp BJ, Spill M, Cole NC, Bahnfleth CL, Butera G, Terry N, Obbagy J. Mayer-Davis E, et al. Alexandria (VA): USDA Nutrition Evidence Systematic Review; 2020 Jul. Alexandria (VA): USDA Nutrition Evidence Systematic Review; 2020 Jul. PMID: 35349233 Free Books & Documents. Review.
Cited by
- Acute Liver Failure Induced by Provitalize: A Menopause Supplement Concocted From Herbs & Probiotics.
Patel R, Hassan A, Scanlan H, Everwine M, Ren Z, Snyder C, ElGenaidi H. Patel R, et al. ACG Case Rep J. 2024 Sep 20;11(9):e01509. doi: 10.14309/crj.0000000000001509. eCollection 2024 Sep. ACG Case Rep J. 2024. PMID: 39310049 Free PMC article. - Insights into the Anti-Adipogenic and Anti-Inflammatory Potentialities of Probiotics against Obesity.
Kober AKMH, Saha S, Ayyash M, Namai F, Nishiyama K, Yoda K, Villena J, Kitazawa H. Kober AKMH, et al. Nutrients. 2024 Apr 30;16(9):1373. doi: 10.3390/nu16091373. Nutrients. 2024. PMID: 38732619 Free PMC article. Review. - Efficacy and Safety of WCFA19 (Weissella confusa WIKIM51) in Reducing Body Fat in Overweight and Obese Adults.
Sun H, Shin J, Kim MJ, Bae S, Lee ND, Yoo B. Sun H, et al. J Clin Med. 2024 Apr 26;13(9):2559. doi: 10.3390/jcm13092559. J Clin Med. 2024. PMID: 38731087 Free PMC article. - A narrative review on the use of probiotics in several diseases. Evidence and perspectives.
Campaniello D, Bevilacqua A, Speranza B, Racioppo A, Sinigaglia M, Corbo MR. Campaniello D, et al. Front Nutr. 2023 Jul 10;10:1209238. doi: 10.3389/fnut.2023.1209238. eCollection 2023. Front Nutr. 2023. PMID: 37497058 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources